OncoFirm™ Proprietary Fluorescent Lateral Flow Antigen Technology
A New Generation of Cancer Diagnostics
Transforming Cancer Biomarker Testing Through Innovation
OncoFirm™ Diagnostics is developing a proprietary fluorescent lateral flow technology platform intended to redefine how cancer biomarkers are detected at the point of care. Our patent-focused diagnostic platform is designed to make cancer screening faster, more accessible, and easier to deploy across diverse healthcare environments.
By combining advanced fluorescence detection with rapid lateral flow assay technology, OncoFirm is building the next generation of in vitro diagnostics (IVD) for oncology—bringing laboratory-quality innovation closer to physicians, clinics, hospitals, and patients.
A Platform Designed for the Future of Oncology Diagnostics
Traditional cancer biomarker testing often requires centralized laboratories, sophisticated instrumentation, lengthy turnaround times, and complex workflows.
OncoFirm’s proprietary platform is being developed to address these challenges by creating rapid, portable diagnostic solutions capable of supporting earlier clinical decision-making and expanding access to biomarker testing where it is needed most.
Our vision is simple:
Bring high-performance cancer biomarker testing directly to the point of care.
The OncoFirm™ Platform Advantage
Our proprietary fluorescent lateral flow platform is designed around four core principles:
Proprietary Fluorescent Detection
Advanced fluorescence-based signal amplification intended to enhance biomarker detection beyond conventional colorimetric rapid tests.
Rapid Point-of-Care Testing
Simple workflows designed to deliver actionable results within minutes rather than days.
Multiplex Biomarker Capability
Platform architecture intended to support multiple cancer biomarkers and future multi-analyte testing applications.
Digital Integration
Designed for compatibility with the OncoFirm™ Electronic Reader, enabling objective fluorescence measurement, digital interpretation, data management, and future connectivity with healthcare information systems.
A Broad Technology Platform
Rather than developing a single diagnostic product, OncoFirm is building a scalable technology platform capable of supporting future diagnostic assays across multiple oncology applications.
Potential areas of development include:
Early cancer screening
Cancer-associated protein biomarkers
Tumor-associated antigen detection
Antibody biomarker assays
Disease monitoring
Companion diagnostics
Precision medicine applications
Clinical research tools
Our platform strategy is intended to enable the development of an expanding portfolio of rapid oncology diagnostics using a common proprietary technology foundation.
Designed for Multiple Healthcare Settings
The flexibility of fluorescent lateral flow technology creates opportunities for deployment across numerous healthcare environments, including:
Hospitals
Physician offices
Oncology practices
Independent laboratories
Community health clinics
Urgent care centers
Mobile healthcare programs
International healthcare markets
Research institutions
By reducing dependence on complex laboratory infrastructure, OncoFirm aims to improve accessibility to advanced cancer biomarker testing.
Intellectual Property Driven
Innovation begins with intellectual property.
OncoFirm™ Diagnostics is pursuing a growing portfolio of patent applications covering novel methods, assay designs, biomarker detection processes, fluorescence technologies, and platform innovations intended to establish long-term competitive advantages.
Our intellectual property strategy is designed to support:
Proprietary assay development
Platform licensing opportunities
Strategic collaborations
Global commercialization
Long-term enterprise value
Positioned Within High-Growth Diagnostic Markets
Global demand for rapid, decentralized diagnostics continues to accelerate, driven by advances in precision medicine, biomarker discovery, personalized oncology, and point-of-care testing.
OncoFirm’s technology platform is being developed at the intersection of several rapidly expanding healthcare sectors:
In Vitro Diagnostics (IVD)
Point-of-Care Diagnostics
Cancer Biomarker Testing
Precision Oncology
Molecular and Protein Biomarkers
Digital Diagnostics
AI-Assisted Diagnostic Interpretation
Personalized Medicine
This convergence creates opportunities for scalable innovation and future product expansion.
Innovation That Starts With Earlier Detection
Earlier identification of clinically relevant cancer biomarkers has the potential to improve clinical workflows and support more informed healthcare decision-making.
OncoFirm is committed to advancing technologies intended to make biomarker testing:
Faster
More accessible
Easier to deploy
More scalable
More cost-efficient
Available closer to patients
We believe the future of oncology diagnostics will be decentralized, digitally connected, and driven by innovative biomarker technologies.
For Strategic Partners and Investors
OncoFirm™ Diagnostics welcomes opportunities to collaborate with:
Healthcare organizations
Cancer research institutions
Diagnostic laboratories
Biotechnology companies
Distribution partners
Clinical collaborators
Strategic investors
Commercialization partners
Together, we aim to accelerate the next generation of rapid cancer diagnostics.
Learn More
Explore our proprietary technology platform, pipeline, and product development efforts throughout the OncoFirm™ Diagnostics website.
For partnership, licensing, investment, or scientific collaboration inquiries, please contact our team.
Forward-Looking Statement
OncoFirm™ Diagnostics is developing proprietary diagnostic technologies that are subject to ongoing research, development, intellectual property protection, validation, and applicable regulatory review. Descriptions of platform capabilities, potential applications, future products, and anticipated performance reflect development objectives and should not be interpreted as claims of current clinical performance or regulatory clearance. Products are not intended for diagnostic use unless and until authorized or approved by the appropriate regulatory authorities.